CORE--ANIMAL MODELS

综合癌症中心（CALLCCC）和生物技术和分子生物学（PMBB）。该设施的目标是以合理的成本向癌症研究人员提供转基因小鼠和支持技术，并支持癌症中心对人类疾病小鼠模型的战略重点。长期目标是建立一个最先进的设施，提供广泛的基因表达和删除策略。对小鼠的实验操作已成为研究癌症机制和产生许多人类疾病模型的有力工具。鉴于广泛 细胞特异性、生理复杂性和癌症发展的动态性质，动物模型可以是病因学、预防和治疗研究中的基本试剂。该机构的目标是：在动物实验的设计和跟踪方面为研究人员提供建议，为个别研究项目生产转基因细胞和动物，提供基本支持技术（例如，配子和胚胎冷冻保存），使用和开发新的试剂和技术（例如，核转移），通过集中功能（如基因分型）降低成本。该核心是由博士特里货车戴克（教师主任）和兰迪daugher（设施主任）。核心通过以合理的成本提供高技能的服务为中心增加了价值。核心支持的研究重点包括胶质母细胞瘤和乳腺癌模型的制作。 Core支持一项新功能，即小鼠基因分型，用于：i）常规和及时的基因分型，以改善菌落管理; ii）标记辅助生成“快速同源”; iii）高通量基因组扫描，以帮助识别修饰基因。核心的未来计划包括ICSI和克隆，基于慢病毒的 转基因、高通量载体构建、新的ES细胞系衍生和基于菌株129的Cre表达系的产生。

Comprehensive Cancer Center (UNC LCCC) and the UNC Program in Biotechnology and Molecular Biology (PMBB). The objective of the facility is to provide genetically modified mice and supporting technologies to UNC researchers at a reasonable cost and to support the Cancer Center's strategic emphasis on mouse models of human disease. The long-term goal is to build a state-of-the-art facility that provides a wide array of gene expression and deletion strategies. Experimental manipulation of the mouse has become a powerful tool for the study of cancer mechanisms and for the generation of many human disease models. Given widespread cell specificity, physiological complexities, and the dynamic nature of cancer development, animal models can be essential reagents in etiologic, prevention and treatment research. The objectives of this facility are to: Advise investigators in the design and follow-up of animal experiments, Generate genetically modified cells and animals for individual research programs, Provide basic support technologies (e.g., gamete and embryo cryopreservation), Use and develop new reagents and technologies (e.g., nuclear transfer), Decrease cost by centralizing functions such as genotyping. The Core is led by Drs. Terry Van Dyke (Faculty Director) and Randy Thresher (Facility Director). The Core adds value to the Center by providing highly skilled services at reasonable costs. Highlights of research supported by the Core include the production of glioblastoma and breast cancer models. The Core supports a new function, mouse genotyping, for: i) routine and timely genotyping to improve colony management; ii) marker-assisted generation of"speed congenics"; and iii) high throughput genome scans to help identify modified genes. Future plans for the Core include ICSI and cloning, lentivirus-based transgenics, high throughput vector construction, new ES cell line derivation and the production of strain 129-based Cre expressing lines.